This will hopefully get the algo’s going in an upward buying trajectory for Clover Health!
UnitedHealth Group (UNH) is scheduled to report its second-quarter 2026 earnings on Thursday, July 16, 2026, before the market opens. Analysts are projecting earnings of $4.84 per share on approximately $110 billion in revenue.
Hopefully some good news/upward stock price momentum for CLOV's quarterly report when it gives its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes!
UnitedHealth Group (UNH) is scheduled to report its second-quarter 2026 earnings on Thursday, July 16, 2026, before the market opens. Analysts are projecting earnings of $4.84 per share on approximately $110 billion in revenue
Elevance Health (ELV) is scheduled to report its second-quarter (Q2) 2026 financial results on Wednesday, July 15, 2026, before the market opens (around 6:00 AM ET)
Molina Healthcare (MOH) will release its second quarter 2026 earnings results after the market closes on Wednesday, July 22, 2026
Humana (NYSE: HUM) is scheduled to report its second-quarter (Q2) 2026 financial results on July 29, 2026. The company will release its earnings report before the market opens at 6:00 a.m. Eastern Time
Any constructive thoughts on what could transpire with solid numbers released by CLOV and other health insurers???
Important To Me: I was wondering how long we will have the majority of CLOV shares locked up which would prevent any premature sale of the company by forced vote. As Vivek has claimed this company will have a higher value in ten years (claim made roughly February 2021) than the highest health insurance company at the time (United Health Group, $332/share), it doesn't give him much time to increase the companies share price substantially before losing his majority share standing.
February 2031 would be the 'rough deadline' if one were to take him at his word and inside knowledge of the company and its true potential. That gives us less than five years to see if that 'pie in the sky' valuation comes to fruition. He recently claimed only last month or so that Clover is 'on track' to make it and reposted his February 2021 future share price claim of Clover.
FYI, this bold claim that Clover Health will surpass the market cap of the highest-valued healthcare insurance company (United Health Group) within 10 years was actually not first voiced by Vivek Garipalli, but rather by his prominent SPAC partner, Chamath Palihapitiya on October 5, 2020, during the official investor conference call and presentation announcing that his blank-check company, Social Capital Hedosophia Holdings Corp. III (IPOC), would be taking Clover Health public.
Clover Health co-founder Vivek Garipalli formally echoed and doubled down on this exact 10-year prediction in a series of communications, most prominently on February 5, 2021. Following a highly critical report by short-seller Hindenburg Research, Garipalli and Chamath Palihapitiya released a comprehensive formal response addressing investors. In this dynamic, Garipalli forcefully defended the 10-year target, reiterating that the legacy footprint of incumbents like United Health Group would be disrupted by Clover's software model.
These are all AI responses.
Vivek Garipalli's Class B shares in Clover Health (NASDAQ: CLOV) convert to Class A common stock automatically on January 7, 2031.
Prior to this date, several specific events can trigger either an optional or automatic conversion of his Class B shares:
Note: Vivek Garipalli currently holds 66.6% of the total voting power in Clover Health (NASDAQ: CLOV), but his voting percentage will collapse to approximately 17.5% after the Class B shares convert in 2031.
Does anyone else have concerns that Clover may be forced to sell itself prematurely before getting to that lofty share price target? Thoughtful responses/discussions appreciated.
+236K Shares Long Since 2020...
for almost one month now. This leads me to strongly believe that it will run up going into early August’s earnings report.
With all the institutional buying many of us feel is currently underway (and will be shown in due time), as well as all the recent positive news that CLOV has been receiving along with ‘unproven rumors’ of potential SAAS deals in the making with large national well known health insurance providers, CLOV’s share price is primed to run up to the low $7’s before 2nd Quarter earnings announcement.
I am unsure however if it then becomes ‘sell on the news’. It depends if they divulge any news on those unfounded SAAS partnerships we are ALL hoping are in fact correct.
What say you???